{"id":"standard-dose-zonisamide","safety":{"commonSideEffects":[{"rate":"17","effect":"Somnolence"},{"rate":"13","effect":"Ataxia"},{"rate":"13","effect":"Dizziness"},{"rate":"13","effect":"Anorexia"},{"rate":"10","effect":"Headache"},{"rate":"9","effect":"Nausea"},{"rate":"6","effect":"Cognitive dysfunction"},{"rate":"1-4","effect":"Nephrolithiasis (kidney stones)"}]},"_chembl":{"chemblId":"CHEMBL750","moleculeType":"Small molecule","molecularWeight":"212.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide works through multiple mechanisms: it blocks voltage-gated sodium channels to reduce repetitive neuronal firing, inhibits T-type calcium channels, and enhances the activity of GABA, the brain's primary inhibitory neurotransmitter. Additionally, it has carbonic anhydrase inhibitory activity and may provide neuroprotection through antioxidant effects.","oneSentence":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:01.486Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial seizures (adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"},{"name":"Lennox-Gastaut syndrome (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT05134857","phase":"PHASE2","title":"The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study","status":"RECRUITING","sponsor":"Washington State University","startDate":"2022-01-07","conditions":"Alcohol Use Disorder (AUD)","enrollment":205},{"nctId":"NCT00777218","phase":"NA","title":"Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine","status":"WITHDRAWN","sponsor":"University of South Alabama","startDate":"2007-08","conditions":"Migraine","enrollment":""},{"nctId":"NCT02220803","phase":"PHASE2","title":"A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2014-03","conditions":"Obstructive Sleep Apnea, Sleep-Disordered Breathing, Blood Pressure","enrollment":13},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT01765608","phase":"PHASE2","title":"Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2010-03","conditions":"Sleep Apnea, Obstructive Sleep Apnea, Obesity","enrollment":50},{"nctId":"NCT01161979","phase":"PHASE1","title":"Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2005-01","conditions":"Healthy","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard zonisamide"],"phase":"marketed","status":"active","brandName":"Standard dose zonisamide","genericName":"Standard dose zonisamide","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition. Used for Partial seizures (adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Lennox-Gastaut syndrome (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}